​

Enanta Pharmaceuticals (ENTA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ENTA Stock Forecast

Enanta Pharmaceuticals (ENTA) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $22.00, with a high of $24.00 and a low of $20.00. This represents a 110.12% increase from the last price of $10.47.

$5 $9 $13 $17 $21 $25 High: $24 Avg: $22 Low: $20 Last Closed Price: $10.47

ENTA Stock Rating

Enanta Pharmaceuticals stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (73.68%), 3 Hold (15.79%), 2 Sell (10.53%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 2 3 14 Strong Sell Sell Hold Buy Strong Buy

ENTA Price Target Upside V Benchmarks

TypeNameUpside
StockEnanta Pharmaceuticals110.12%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts112
Avg Price Target$20.00$20.00$22.00
Last Closing Price$10.47$10.47$10.47
Upside/Downside91.02%91.02%110.12%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25232--7
Sep, 25222--6
Aug, 25221--5
Jul, 25121-15
Jun, 25122-16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 01, 2025Akash TewariJefferies$20.00$10.8883.82%91.02%
Jun 03, 2025Roy BuchananJMP Securities$24.00$7.19233.80%129.23%
Dec 09, 2022H.C. Wainwright$56.00$41.9633.46%434.86%
Nov 22, 2022RBC Capital$54.00$46.4016.38%415.76%
Jul 29, 2022Yasmeen RahimiPiper Sandler$87.00$51.2869.66%730.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 01, 2025JefferiesBuyupgrade
Sep 02, 2025WestPark CapitalBuyinitialise
May 14, 2025CitigroupOutperformOutperformhold
Oct 09, 2024JMP SecuritiesMarket OutperformMarket Outperformhold
Feb 08, 2023Piper SandlerOverweightOverweighthold
Nov 22, 2022RBC CapitalSector PerformSector Performhold
Jul 29, 2022Piper SandlerOverweightOverweighthold
Jul 06, 2022Evercore ISIOutperformupgrade

Financial Forecast

EPS Forecast

$-11 $-9 $-7 $-5 $-3 $-1 $0 Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-3.92$-5.91$-6.38$-5.48-----
Avg Forecast$-3.86$-4.68$-7.23$-5.28$-4.87$-4.26$-3.48$-7.36$-6.62
High Forecast$-3.14$-3.74$-6.97$-4.81$-4.53$-2.52$-0.99$-4.70$-4.23
Low Forecast$-6.20$-5.62$-7.40$-5.60$-5.34$-6.74$-8.70$-10.43$-9.38
Surprise %1.55%26.28%-11.76%3.79%-----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$97.07M$86.16M$79.20M$67.64M-----
Avg Forecast$99.90M$97.06M$77.13M$71.21M$65.39M$58.18M$64.98M$37.53M$35.61M
High Forecast$146.47M$116.47M$80.99M$72.18M$73.40M$90.10M$65.88M$49.59M$47.06M
Low Forecast$85.53M$77.65M$69.50M$70.70M$57.55M$32.04M$64.08M$27.12M$25.73M
Surprise %-2.83%-11.23%2.69%-5.02%-----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-79.00M$-121.75M$-133.82M$-116.05M-----
Avg Forecast$-92.73M$-107.33M$-138.24M$-116.05M$-104.47M$-134.65M$-128.10M$-155.72M$-140.06M
High Forecast$-74.18M$-85.86M$-110.59M$-101.81M$-95.90M$-53.28M$-20.87M$-99.54M$-89.53M
Low Forecast$-111.28M$-128.79M$-165.88M$-118.46M$-113.04M$-142.69M$-184.15M$-220.75M$-198.56M
Surprise %-14.81%13.44%-3.20%------

ENTA Forecast FAQ

Is Enanta Pharmaceuticals stock a buy?

Enanta Pharmaceuticals stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 3 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Enanta Pharmaceuticals is a favorable investment for most analysts.

What is Enanta Pharmaceuticals's price target?

Enanta Pharmaceuticals's price target, set by 19 Wall Street analysts, averages $22 over the next 12 months. The price target range spans from $20 at the low end to $24 at the high end, suggesting a potential 110.12% change from the previous closing price of $10.47.

How does Enanta Pharmaceuticals stock forecast compare to its benchmarks?

Enanta Pharmaceuticals's stock forecast shows a 110.12% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Enanta Pharmaceuticals over the past three months?

  • October 2025: 28.57% Strong Buy, 42.86% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 40.00% Strong Buy, 40.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Enanta Pharmaceuticals’s EPS forecast?

Enanta Pharmaceuticals's average annual EPS forecast for its fiscal year ending in September 2025 is $-4.87, marking a -11.13% decrease from the reported $-5.48 in 2024. Estimates for the following years are $-4.26 in 2026, $-3.48 in 2027, $-7.36 in 2028, and $-6.62 in 2029.

What is Enanta Pharmaceuticals’s revenue forecast?

Enanta Pharmaceuticals's average annual revenue forecast for its fiscal year ending in September 2025 is $65.39M, reflecting a -3.31% decrease from the reported $67.64M in 2024. The forecast for 2026 is $58.18M, followed by $64.98M for 2027, $37.54M for 2028, and $35.61M for 2029.

What is Enanta Pharmaceuticals’s net income forecast?

Enanta Pharmaceuticals's net income forecast for the fiscal year ending in September 2025 stands at $-104M, representing a -9.97% decrease from the reported $-116M in 2024. Projections indicate $-135M in 2026, $-128M in 2027, $-156M in 2028, and $-140M in 2029.